title: Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
abstract: Nasal administration has emerged as a promising and attractive route for vaccination, especially for the prophylaxis of respiratory diseases. Our previous studies have shown that severe acute respiratory syndrome coronavirus (SARS-CoV) virus-like particles (VLPs) can be assembled using a recombinant baculovirus (rBV) expression system and such VLPs induce specific humoral and cellular immune responses in mice after subcutaneous injection. Here, we investigated mucosal immune responses to SARS-CoV VLPs in a mouse model. Mice were immunized in parallel, intraperitoneally or intranasally, with VLPs alone or with VLPs plus cytosine-phosphate-guanosine (CpG). Immune responses, including the production of SARS-CoV-specific serum immunoglobulin G (IgG) and secretory immunoglobulin A (sIgA), were determined in mucosal secretions and tissues. Both immunizations induced SARS-CoV-specific IgG, although the levels of IgG in groups immunized via the intraperitoneal (i.p.) route were higher. sIgA was detected in saliva in groups immunized intranasally but not in groups immunized intraperitoneally. CpG had an adjuvant effect on IgA production in genital tract washes when administered intranasally but only affected IgA production in faeces samples when administered intraperitoneally. In addition, IgA was also detected in mucosal tissues from the lung and intestine, while CpG induced an increased level of IgA in the intestine. Most importantly, neutralization antibodies were detected in sera after i.p. and intranasal (i.n.) immunizations. Secretions in genital tract washes from the i.n. group also showed neutralization activity. Furthermore, VLPs that were administered intraperitoneally elicited cellular immune responses as demonstrated by enzyme-linked immunospot (ELISPOT) assay analyses. In summary, our study indicates that mucosal immunization with rBV SARS-CoV VLPs represent an effective means for eliciting protective systemic and mucosal immune responses against SARS-CoV, providing important information for vaccine design.
authors.affiliation: State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan.
authors.forename: Baojing
authors.initials: B
authors.lastname: Lu
authors.forename: Yi
authors.initials: Y
authors.lastname: Huang
authors.forename: Li
authors.initials: L
authors.lastname: Huang
authors.forename: Bao
authors.initials: B
authors.lastname: Li
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Zheng
authors.forename: Ze
authors.initials: Z
authors.lastname: Chen
authors.forename: Jianjun
authors.initials: J
authors.lastname: Chen
authors.forename: Qinxue
authors.initials: Q
authors.lastname: Hu
authors.forename: Hanzhong
authors.initials: H
authors.lastname: Wang
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D016367:Baculoviridae; D004195:Disease Models, Animal; D005260:Female; D018928:Immunity, Mucosal / Q000187:drug effects / Q000276:immunology*; D007114:Immunization / Q000379:methods; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000493:pharmacokinetics*; D045473:Severe acute respiratory syndrome-related coronavirus / Q000235:genetics / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000097:blood / Q000276:immunology* / Q000517:prevention & control; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology / Q000493:pharmacokinetics*
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; C408982:CPG-oligonucleotide; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009838:Oligodeoxyribonucleotides; D014765:Viral Vaccines
references.citation: Proteomics. 2004 Feb;4(2):492-504
references.pmid: 14760722
references.citation: Clin Vaccine Immunol. 2007 Jul;14(7):894-901
references.pmid: 17494640
references.citation: J Immunol. 1998 Nov 1;161(9):4463-6
references.pmid: 9794366
references.citation: J Virol. 1998 Oct;72(10):8220-9
references.pmid: 9733865
references.citation: J Immunol. 1998 Jan 15;160(2):870-6
references.pmid: 9551923
references.citation: Methods. 2006 Sep;40(1):60-5
references.pmid: 16997714
references.citation: Cell. 1989 Oct 6;59(1):103-12
references.pmid: 2676191
references.citation: Biochem Biophys Res Commun. 2004 Jun 11;318(4):833-8
references.pmid: 15147946
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7956-61
references.pmid: 12060741
references.citation: Vaccine. 2008 Aug 19;26 Suppl 10:K53-61
references.pmid: 18847557
references.citation: Vaccine. 1998 Jul;16(11-12):1216-24
references.pmid: 9682382
references.citation: J Immunol. 2001 Mar 1;166(5):3451-7
references.pmid: 11207303
references.citation: Viral Immunol. 2008 Mar;21(1):27-37
references.pmid: 18355120
references.citation: Science. 2003 May 30;300(5624):1394-9
references.pmid: 12730500
references.citation: Vaccine. 2003 Sep 8;21(25-26):3885-900
references.pmid: 12922123
references.citation: J Biol Chem. 2005 Aug 19;280(33):29588-95
references.pmid: 15980414
references.citation: Nature. 1995 Apr 6;374(6522):546-9
references.pmid: 7700380
references.citation: Immunobiology. 1992 Feb;184(2-3):157-79
references.pmid: 1587541
references.citation: J Virol. 2005 Sep;79(18):11638-46
references.pmid: 16140741
references.citation: Proc Natl Acad Sci U S A. 1997 May 13;94(10):5267-72
references.pmid: 9144226
references.citation: Vaccine. 2006 Jan 30;24(5):652-61
references.pmid: 16214268
references.citation: Eur J Immunol. 2008 Jan;38(1):114-26
references.pmid: 18081037
references.citation: Arch Virol. 2005 Feb;150(2):341-9
references.pmid: 15578236
references.citation: N Engl J Med. 2003 May 15;348(20):1967-76
references.pmid: 12690091
references.citation: PLoS One. 2008 Jul 16;3(7):e2685
references.pmid: 18628832
references.citation: Science. 2002 Apr 12;296(5566):356-9
references.pmid: 11896235
references.citation: Immunology. 2007 Dec;122(4):496-502
references.pmid: 17680799
references.citation: FEBS Lett. 2004 Oct 8;576(1-2):174-8
references.pmid: 15474033
references.citation: Virology. 2009 Jun 5;388(2):344-53
references.pmid: 19409593
references.citation: J Virol. 2005 Nov;79(22):13915-23
references.pmid: 16254327
references.citation: Vaccine. 2009 Apr 14;27(17):2326-34
references.pmid: 19428847
references.citation: Nature. 2004 Apr 1;428(6982):561-4
references.pmid: 15024391
references.citation: J Biotechnol. 2005 Oct 17;120(1):72-82
references.pmid: 16023241
references.citation: Science. 2003 May 30;300(5624):1399-404
references.pmid: 12730501
references.citation: Proc Natl Acad Sci U S A. 2003 May 27;100(11):6753-8
references.pmid: 12748380
references.citation: Lancet. 2003 Apr 19;361(9366):1319-25
references.pmid: 12711465
references.citation: J Virol. 2003 Mar;77(6):3615-23
references.pmid: 12610137
references.citation: J Virol. 2004 Jul;78(13):6995-7003
references.pmid: 15194776
references.citation: Cell Immunol. 1998 Nov 25;190(1):77-82
references.pmid: 9826449